CCDRD AG has extensive experience with generic Salmeterol/Fluticasone inhalation product development compared to the available DPI and MDI reference products.

• 25 trials performed with Salmeterol/Fluticasone DPI and MDI inhalers in healthy subjects
• systemic safety and pulmonary deposition studies
• highly experienced investigators and study teams in the phase I units available
• standardized training and clinical procedures
• intrasubject and residual variance data available
• information about product aging available